VAXCYTE, INC. – Trademark Portfolio

Entity Type: 03

VAXCYTE, INC. holds 12 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 9 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 6 trademarks are registered and 3 are pending. Notable registered marks include ECRM, VAXCYTE, and PROTECT HUMANKIND. The owner is based in San Carlos, CA.

825 Industrial Road, Suite 300

San Carlos, CA 94070

12 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

VAXCYTE, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (9 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

42
Computer & Scientific (6 filings)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does VAXCYTE, INC. have?

VAXCYTE, INC. has 12 U.S. trademarks filed with the USPTO. Of these, 6 registered, 3 pending, 3 abandoned.

What trademark classes does VAXCYTE, INC. file in?

VAXCYTE, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are VAXCYTE, INC.'s most well-known trademarks?

VAXCYTE, INC.'s registered trademark portfolio includes well-known marks such as ECRM, VAXCYTE, and PROTECT HUMANKIND. These are among 6 currently registered trademarks in the portfolio.

What is VAXCYTE, INC.'s trademark registration success rate?

VAXCYTE, INC. has a 67% trademark registration rate, with 6 out of 9 resolved applications resulting in successful registration. Currently, 3 applications are pending review.